Latest News Releases 7 August

Lung cancer screening using low-dose computed tomography would prevent more than 18,000 premature lung cancer deaths at a cost of approximately €937 million if half of the eligible population were screened, according to a report presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer.

The use of Stereotactic Body Radiotherapy (SBRT) for patients with non-small cell lung cancer can reduce treatment disparities between White and Black patients, according to research presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

Using sotorasib as a lead-in therapy with pembrolizumab or atezolizumab for patients with advanced KRAS p.G12C non-small cell lung cancer demonstrated durable clinical activity with lower rates of grade 3-4 treatment-related adverse events compared to patients who received these therapies concurrently, according to research presented today at the IASLC World Conference on Lung Cancer 2022.

Younger patients with lung cancer are significantly more likely than older patients to be diagnosed with later stages of disease, illustrating the need to develop strategies to increase the early detection of lung cancer among younger patients who are currently ineligible for lung cancer screening.

Personalized medicine for lung cancer using molecular-targeted drugs is common but there have been no prospective validation studies done on the usefulness of lung cancer gene panel testing using cytology samples.

Using data from the National Lung Screening Trial, researchers found that the incidence of second primary lung cancer was approximately 4% among the entire cohort of lung cancer patients and was as high as 8% among patients undergoing surgery for stage IA disease.